

References

I-129

1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; May 2014.
2. U.S. Food and Drug Administration (FDA). FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. FDA News. Silver Spring, MD: FDA. May 2014.
3. Rezaie A. Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases. *Annals of Gastroenterology*. 2014; 27: 179-180.
4. Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013; 369(8): 699-710.
5. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2013; 369: 711-721.
6. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. *Ther Adv Gastroenterol*. 2015; 8(2): 66–82.
7. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*. 2014; 147: 618–627.
8. Vedolizumab. Clinical Pharmacology.
9. Vedolizumab. DrugPoints Summary. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO.